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Introduction: There are widespread moves to develop risk-stratified approaches to population-based breast screening. The
public needs to favour receiving breast cancer risk information, which ideally should produce no detrimental effects. This study
investigates risk perception, the proportion wishing to know their 10-year risk and whether subsequent screening attendance is
affected.
Methods: Fifty thousand women attending the NHS Breast Screening Programme completed a risk assessment questionnaire.
Ten-year breast cancer risks were estimated using a validated algorithm (Tyrer-Cuzick) adjusted for visually assessed
mammographic density. Women at high risk (X8%) and low risk (o1%) were invited for face-to-face or telephone risk feedback
and counselling.
Results: Of those invited to receive risk feedback, more high-risk women, 500 out of 673 (74.3%), opted to receive a consultation
than low-risk women, 106 out of 193 (54.9%) (Po0.001). Women at high risk were significantly more likely to perceive their risk as
high (Po0.001) and to attend their subsequent mammogram (94.4%) compared with low-risk women (84.2%; P¼ 0.04) and all
attendees (84.3%; p0.0001).
Conclusions: Population-based assessment of breast cancer risk is feasible. The majority of women wished to receive risk
information. Perception of general population breast cancer risk is poor. There were no apparent adverse effects on screening
attendance for high-risk women whose subsequent screening attendance was increased.
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UK deaths from breast cancer have declined by 40% in women
o70 years. Some of this fall is attributed to mammographic
screening, but widespread use of adjuvant systemic therapies and
general improvements in care have also contributed (Parkin et al,
2005; Cancer Research UK, 2014). Unlike many national breast
screening programmes, which typically use one or two yearly
intervals, the interval between mammograms in the UK National
Health Service Breast Screening Programme (NHSBSP) is 3 years.
There is evidence that women at high risk of breast cancer
(30%þ lifetime risk or 8% 10-year risk – NICE guidelines;
McIntosh et al, 2004 updated 2006 and 2013) are more likely to
develop interval cancers (Nixon et al, 2000) and reducing the
screening interval in this poor prognosis group may be indicated
(Porter et al, 2007; Bennett et al, 2011). The Swedish two-county
study showed women with a positive family history of breast
cancer were more likely to develop breast cancer between their
two-yearly screens than women with negative family histories
(Nixon et al, 2000). High mammographic density also increases the
chances of developing breast cancers as well as interval cancers
due possibly to masking effects, suggesting density should be
incorporated into risk models (Mandelson et al, 2000; Ciatto et al,
2004). Stratification of screening frequency by risk is likely to be
cost effective (Schousboe et al, 2011; Pharoah et al, 2013).
Breast cancer risk is generally assessed using models that include
breast cancer family history, reproductive and hormonal history
(age at first pregnancy, menarche, menopause, HRT use), height
and weight (Gail et al, 1989; Costantino et al, 1999; Tyrer et al,
2004; Amir et al, 2010). Models generally perform well for
predicting risk in a population (e.g., 1 in 3 lifetime risk) but not for
precise individual risk (Amir et al, 2010).
In the USA, the Gail model is widely used. It is based on age,
first-degree relatives with breast cancer, number of surgical breast
biopsies and reproductive factors as above (Gail et al, 1989;
Costantino et al, 1999). In a comparison of models using UK
data, we demonstrated that for women with a family history of
breast cancer the Tyrer-Cuzick model performed better than the
Gail model; similar results were reported with US data (Boyd
et al, 2002; Amir et al, 2003). The Tyrer-Cuzick model has a more
extensive familial component and includes HRT, height and
weight (Tyrer et al, 2004). Nevertheless, many breast cancers
arise in women with no commonly assessed risk factors (Amir
et al, 2003).
Mammographic density is an assessable risk factor with the
largest population attributable risk and is substantially
heritable (Pankow et al, 1997; Boyd et al, 2002). The difference
in risk between women with extremely dense, as opposed to
predominantly fatty breasts, is approximately four- to six-fold
(Santen et al, 2007). Incorporating density into models increases
their predictive values (Barlow et al, 2006; Chen et al, 2006).
There are international moves to promote risk-stratified
screening, particularly for breast cancer (Schousboe et al, 2011;
Evans et al, 2012). For this to happen, risk must be estimated in
individuals, communicated to them and to organisers of screening
programmes. Breast cancer risk may be assessed best in the context
of the screening programme. Here we report the feasibility of this
approach in a large population of women screened in northwest
England. Since previous studies indicated adding an assessment of
mammographic density improved a model’s discriminatory power,
we also assessed the feasibility of obtaining an estimate of visually
assessed mammographic density (Gilbert et al, 2006). Public
opinion needs to favour receiving breast cancer risk information if
it is to be introduced into screening programmes. Finally, there
must be no substantial adverse effects, such as decreased
subsequent screening uptake. Specific research questions are: is it
feasible to deliver risk assessment in the NHSBSP? Do women
want to know their 10-year breast cancer risk estimate? And, does
knowing one’s risk affect screening attendance?
MATERIALS AND METHODS
All women aged 46–73 years (n¼ 187 466) in 15 screening areas
across Greater Manchester invited for routine three-yearly
mammographic screening were identified through the UK
NHSBSP. Recruitment took place between October 2009 and
February 2013. Before screening, 131 373 were mailed information
about the Predicting Risk of Cancer At Screening (PROCAS) study,
a consent form and questionnaire (http://www.uhsm.nhs.uk/
research/Documents/PROCAS%20Questionnaire.pdf). The con-
sent process made clear that participants’ breast cancer risk would
be assessed and that usual breast cancer screening would continue
for non-participants.
Fifty thousand women brought their completed questionnaires
to their screening appointment and consented to PROCAS at the
time of mammography. A breakdown of participant ages and
screening area can be found in Table 1. Questionnaires were
entered into the study database, and 10-year breast cancer risk
was estimated automatically using the Tyrer-Cuzick model (Tyrer
et al, 2004). Participants had at least two opportunities to opt-out
of receiving personal breast cancer risk information; first at the
time of initial consent (by not ticking a box ‘I wish to know my
risk’) and later by contacting the study coordinator.
All women with a X8% 10-year risk (Tyrer-Cuzick) of
developing breast cancer who were alive and did not have previous
or current cancer (673), and a subset (first 93) of those with
5–7.99% 10-year risk and at least 60% mammographic density
(high-risk), were invited to receive risk counselling (Figure 1).
We were informed by women, their GPs or by checking for updates
in the National Breast Screening Service database if women moved
Table 1. Participant ages, ethnicity and screening location
Age Number Percentage
% of those
attended
screening
o50 3690 7.4 6.4
50–54 12909 25.8 26.2
55–59 10793 21.6 21.0
60–64 11151 22.3 21.0
65–69 8518 17.0 17.1
70þ 2939 5.9 8.3
Ethnicity
Percentage
GMRa
White 45 538 91.1 82.8
Black or Black British 516 1.0 2.76
Asian or Asian British 679 1.4 10.15
Mixed 249 0.5 2.26
Jewish 455 0.9 1.2
Other 733 1.5 1
Data not known 1830 3.7
Area
% of those
attended screening
Manchester 20 897 41.8 40.2
Salford 7914 15.8 17.1
Trafford 3723 7.5 16.5
Tameside 8695 17.4 17.4
Oldham 8758 17.5 8.8
Other 13 0.0
aPercentage of the population within the Greater Manchester region (GMR) in each ethnic
group. N.B. there are no details held on ethnicity of invitees for screening and it is likely that
certain ethnicities, particularly Asian, are under-represented in the older age groups.
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out of the screening area. Sixteen women moved out of area and
were excluded from further participation. Six did not move out of
area but had changed health authority, and therefore screening
service. Women were sent a letter explaining the study and were
asked to indicate whether they wished to receive risk counselling.
Women failing to respond to two invitations were considered as
non-responders (Figure 1). In order that participants did not
assume their invitation indicated high risk the Patient Information
Sheet stated that all women at high risk and a selection of those at
low risk would be invited to receive risk counselling. Thus, a subset
(first 193) of women screened with a p1.5% 10-year risk (Tyrer-
Cuzick) and o10% density were also invited (low-risk), and
provided a comparison group. A total of 959 women were given
the option of either face-to-face or telephone feedback and risk
counselling (see Table 2) by a clinician experienced in risk
communication (DGRE and AH). Risk appointments followed a
standardised format, based on Leventhal’s common sense model of
self-regulation of health and illness (Leventhal et al, 2001), with
visual representations of the Tyrer-Cuzick risk curve being sent to
telephone participants after their appointment. Risk consultations
were carried out between March 2010 and August 2014.
Screened and invited to join PROCAS: 131 373
Actual uptake: 50 000†
Original Tyrer-Cuzick 10-year risk
of 5-7.99% (moderately increased
risk): 4230
Original Tyrer-Cuzick 10-year risk
of 8% (high risk): 734
Original Tyrer-Cuzick 10-year risk
of 5–7.99% and mammographic
density 60%: 223
Wanted to know risk at point
of risk appointment invite: 706
Wanted to know risk at point of
risk appointment invite: 4058
Wanted to know risk at point of
risk appointment invite: 1676
Not invited:
16 previous
cancers
14 current
cancers
1 no longer
high risk
Number invited: 673 Number invited: 93* Number invited: 193*
Not
attended: Not
attended: Notattended:54 declined
7 declined103 no
response 16 no
response
2 did not
attend
25 declined
56 no
response
6 did not
attend
Number attended or
telephoned: 68
Number attended or
telephoned: 106
Number attended or
telephoned: 500
Number still in each risk
category after assessment:
Number still in each risk
category after assessment:
Number still in each risk
category after assessment:
322 high risk
160 moderate risk
18 average risk
0 low risk
6 high risk
54 moderate risk
8 average risk
0 low risk
0 high risk
0 moderate risk
17 average risk
89 low risk
6 did not
attend
10 in
progress
2 deceased
Original Tyrer-Cuzick 10-year
risk of <1.5% (low risk): 1766
Figure 1. Consort diagram for first 50 000 in PROCAS. wOriginal Tyrer-Cuzick 10-year risk of 2–4.99% (average risk): 43 270 not included.
*The intention was to invite a small proportion of moderately increased risk with a mammographic density ofX60% and low-risk participants, which is
why we did not invite the full number of participants in these groups for feedback appointments. No response was to two letter invitations.
Table 2. Information discussed at risk assessment
appointments
All women (high and low)
Their 10-year and lifetime risk of breast cancer
What factors – hormonal, reproductive, lifestyle, mammographic density and
family history – increased or decreased their risk
How future breast cancer risk could be reduced by diet and lifestyle changes –
reduced alcohol, more exercise, maintaining a healthy weight or losing weight
High-risk women
Extra mammographic screening if aged o60 years of age
Chemoprevention with tamoxifen and more recently raloxifene (there is no
guidance on aromatase inhibitors in the UK)
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Women not invited for risk counselling are in the process of
receiving their risk by letter. The PROCAS study was approved by
Central Manchester Research Ethics Committee (Ref: 09/H1008/
81; Evans et al, 2012).
Assessment of mammographic density. Mammographic density
(percent dense area) was assessed using linear visual-analogue
scales during film reading by two readers from a pool of 18 readers
(nine radiologists, two breast physicians and seven advanced
radiography practitioners), working independently as previously
described (Gilbert et al, 2006; Duffy et al, 2008). Women with
breast density of 460% and a 10-year Tyrer-Cuzick risk of
5–7.99% were considered high risk with an adjusted 10-year
estimate of 48%. Women with breast density of o10% and a
Tyrer-Cuzick 10-year risk ofo1.5% were considered low risk with
an adjusted 10-year risk of below 1%. These adjustments take into
account thato10% density is in the lowest fifth and460% density
in the highest fifth of mammographic density at all ages and would
be expected to reduce or increase risk by at least 60%, respectively.
Risk perception. Women attending face-to-face appointments
were asked to complete a previously validated risk perception
questionnaire prior to their risk counselling (Evans et al, 1993,
1994; Hopwood et al, 2001). Women were asked to choose a
category indicating their risk compared with the population
average (comparative risk) and perceived lifetime risk (absolute
risk) for themselves and for women in the general population. The
categories given for absolute risk ratings were: ‘inevitable’, ‘1 in 2’,
‘1 in 8 through 1 in 10’, to ‘1 in 200’ and ‘very unlikely’ (see Table 3
for full range of values). Although the main measure of risk in the
present study was 10-year risk, we also gave residual lifetime risk
figures to women as part of their risk feedback.
Breast cancers. We are automatically informed of breast cancers
in subjects identified on screening. Interval cancers are notified to
us by subjects and also from regular checks on the North West
Cancer Intelligence Service.
Statistics. Fisher’s exact test was used to make two-by-two
comparisons (e.g., below average vs above average, 41 in 8 vs
o1 in 10). A chi-square test for linear trend was used to compare
ordered categorical data. Differences in independent proportions
with approximate binomial confidence intervals uptake of risk
counselling and subsequent screening, compared with the high risk
group (Miettinen and Nurminen, 1985). All statistical tests
were two-sided and a P-value of o0.05 considered as statistically
significant. StatsDirect version 3 (StatsDirect Ltd, www.
statsdirect.com) was used for statistical analysis. A sample size of
176 participants in each group was required to detect a 15%
difference in uptake to counselling between the high- and low-risk
groups based on a 70% response rate in the high-risk group, with
80% power and a confidence level of 95%.
RESULTS
Of 187 466 women invited for mammography between October
2009 and February 2013, 131 373 attended their screening
appointment and were invited to join the PROCAS study. Fifty
thousand women consented (38% of screening attendees)
(Figure 1). Their ages ranged from 46 to 84 years (a small number
aged 473 opted into screening/PROCAS), with a median age at
entry of 58 years. Of those consenting 11 852 (23.7%) were
Table 3. Risk perception in high- and low-risk women
High X8% 10-year risk not
seen in FHC previously
High X8% 10-year risk for those
previously seen in FHC
Low o1%
10-year risk
Number 275 53 58
Comparative risk perception
(a) Above average risk 156 (57%) 35 (66%) 3 (5%)
(b) Average risk 105 (38%) 17 (32%) 38 (66%)
(c) Below average risk 10 (4%) 1 (2%) 17 (29%)
Not filled in 4 (2%) 0 0
Chi square for trend compared with low-risk group 71.9 45.7
P-value for chi square for trend compared with low-risk group Po0.001 Po0.001
P-value for above average risk (a) vs below average risk
(c) compared with low-risk group
Po0.001 Po0.001
Perception of individual lifetime risk
(a) 41 in 4 (inevitable, 1 in 2, 1 in 3) (30–100%-high) 16/264 (6%) 6/50 (12%) 1/57 (2%)
(b) 1 in 4 1 in 5 or 1 in 6 (18–25% moderate) 96 (36%) 26 (51%) 11 (19%)
(c) Between 1 in 8 and 1 in 10 population risk (10–12%) 68 (26%) 7 (14%) 11 (19%)
(d) Between 41 in 10 and o1 in 50 Includes 1 in 20 32 (12%) 4 (8%) 3 (5%)
(e) p1 in 50 (1 in 100; 1 in 200, very unlikely) 52 (20%) 7 (14%) 31 (54%)
Chi square for trend compared with low-risk group 22.4 20.8
P-value for chi square for trend compared with low-risk group Po0.001 Po0.001
P-value for 41 in 8 (aþb) vs o1 in 10 (dþ e) compared with
low-risk group
Po0.001 Po0.001
Perception of population lifetime risk
(a) 41 in 4 2/270 (1%) 0/50 (0%) 0/58 (0%)
(b) Between 1 in 4 and 1 in 6 65 (24%) 11 (22%) 12 (21%)
(c) Between 1 in 8 and 1 in 10 99 (37%) 26 (52%) 19 (33%)
(d) Between o1 in 10 and 41 in 50 32 (12%) 3 (6%) 6 (10%)
(e) p1 in 50 72 (27%) 10 (20%) 21 (36%)
Chi square for trend compared with low-risk group 1.7 2.3
P-value for chi square for trend compared with low-risk group P¼0.18 P¼0.13
P-value for 41 in 8 (aþb) vs o1 in 10 (dþ e) compared with
low-risk group
P¼0.36 P¼0.29
P-value for population risk (c) vs o1 in 10 (dþ e) compared
with low-risk group
P¼0.41 P¼0.03
Abbreviation: FHC¼Family History Clinic.
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attending their first screen and the remainder (76.7%) attending an
incident screen.
Identification and counselling of high- and low-risk women.
Two groups of women were identified as having high breast cancer
risk; those with a Tyrer-Cuzick 10 year risk of X8%, and those
with a Tyrer-Cuzick risk of 5–7.99% plus mammographic density
X60%. There were 734 (1.5%) with a Tyrer-Cuzick 10 year risk
X8% and 223 (0.45%) with a Tyrer-Cuzick risk of 5–7.99% plus
mammographic densityX60%, 957 in total. Of these 957, 766 were
invited to discuss their risk with a clinician (DGRE/AH; Figure 1).
A further 193 women from the low-risk group were invited to
discuss their risk and to give reasonable power to differentiate
uptake between the high- and low-risk groups. We halted inviting
those with a Tyrer-Cuzick risk of 5–7.99% plus mammographic
density X60% at 93 as there were no differences between this
group and the high-risk group.
Women were give the option of receiving their risk by telephone
or face-to-face appointment. Of women with a Tyrer-Cuzick
10-year risk X8%, 271 chose telephone vs 229 face-to-face
consultations. Of women with a Tyrer-Cuzick score of 5–7.99%
and X60% density, 37 chose telephone vs 31 face-to-face consulta-
tions. Of women with a Tyrer-Cuzick score of o1.5% and o10%
density, 70 chose telephone vs 36 face-to-face consultations. There
was no significant difference in method of risk delivery between the
three groups (chi square¼ 5.06, P¼ 0.08).
High-risk women. Of women with Tyrer-Cuzick 10-year risk
X8%, 706 out of 734 (96.2%) originally indicated that they wanted
risk feedback, 33 were ineligible and thus 673 were invited for
counselling (Table 4; Figure 1). Of these, 163 (24.2%) declined or
did not attend their risk appointment. The remainder attended or
had telephone risk counselling, with 10 still in progress. Twenty-
eight non-attenders had previously attended our Family History
Clinic (FHC). A similar proportion with Tyrer-Cuzick score
of 5–7.99% andX60% density originally wanted to know their risk
(95.9%), and 68 out of 93 (73.1%) attended.
Thus far, 568 high risk women have received risk counselling
during which questionnaire details (family history, individual
hormonal and lifestyle factors) were confirmed. Consequently, a
number of women (160 out of 500, 32%) originally identified as
high-risk (Tyrer-Cuzick score 48%) were re-assessed as moder-
ately increased risk (Tyrer-Cuzick score 5–7.99%) and 18 out of
500 (3.6%) as average risk, based on Tyrer-Cuzick risk program v6.
For the original 500 with X8% 10-year risk there was a mean
reduction in 10-year risk of 1.3% after addition of further
unaffected female relatives and adjustment of other risk factors.
Of those seen with (5–7.99%) risk and 460% density, 8 out of 68
(12%) fell below the 5% 10-year risk on re-evaluation and thus
dropped out of the high-risk group (Figure 1).
Referral for additional 12–18-monthly screening as indicated in
NICE guidelines (only eligible aged o60 years) was offered to 383
eligible women in both high-risk categories of which 4 declined, and
298 (77.8%) have taken up the offer. Forty were already receiving
screening through the FHC. Thus 338 of 383 (88.2%) are having
additional screening. In this group, four small breast cancers were
detected on the interval 18-month breast screen (Table 5).
Low-risk women. Of those at low-risk (Tyrer-Cuzick score of
o1.5% ando10% density), 94.9% originally wished to know their
risk. A total of 193 were offered risk consultation and 106 out of
193 (54.9%) attended a risk appointment. Women at high risk were
significantly more likely to attend a risk appointment/telephone
call than women at low risk (Table 4; Po0.0001).
Cancers. Overall, 26 cancers (3.9%) occurred in the 673 eligible
women with an original Tyrer-CuzickX8% 10-year risk (Table 4).
Thirteen were identified on a mammogram at study entry, four on
an interval mammogram and nine on their subsequent follow-up
mammogram after 3 years. There were 87 cancers (2.1%) in the
4230 women with a Tyrer-Cuzick 5–7.99% 10-year risk, of which
41 were identified at study entry, 20 between screens and 26 on their
subsequent three yearly mammogram. Six occurred in women with
increased mammographic density (X60%) (Table 4). There were
only 18 breast cancers (1.0%) in the 1766 women with o1.5%
10-year risk of which 8 were identified at study entry, 4 between
screens and 6 on their subsequent screening mammogram, and only
2 cancers occurred in those with mammographic density o10%.
Table 4. Uptake of risk counselling and next round screening in attendees of risk counselling
Number
Number
invited
Uptake of risk
counselling,
compared with high
risk
Uptake of next
screening round,
compared with high risk
attendeda
All breast
cancers
since
entry
Percentage
with breast
cancer
High risk 8%þ 734 673 500 (74.3%)* 271/287 (94.4%)** 26/673 3.9
Moderate risk 223 93 68 (73.1%) 56/58(96.5%) 6/223 2.7
5–7  9% X60% density Difference: 1.2%
(95% CI 8% to 11%)*
Difference: 2.1%
(95% CI 6% to 6%)**
P¼0.8 P¼0.54
Low risko1% (o1  5% witho10% density) 271 193 106 (54.9%) 64/76 (84.2%) 2/271 0.7
Difference: 19.4%
(95% CI 12–27%)*
Difference: 10.2%
(95% CI 3–20%)**
Po0.001 P¼0.004
High-risk non-attenders (i.e., those invited
to a risk appointment but did not attend)
173 — 0 89/115 (77.4%)
Difference: 17.0%
(95% CI 9% to 26%)**
Po0.0001
—
Low-risk non-attenders (i.e., those invited
to a risk appointment but did not attend)
87 — 0 55/69 (79.7%)
Difference: 14.7%
(95% CI 6% to 26%)**
—
P¼0.0002
All women in Greater Manchester who
attended previous round 2012–2013
39 058 — — 32925 (84.3%)
Difference: 10.1%
(95% CI 7% to 12%)**
Po0.0001
—
Key: comparisons of the difference between independent proportions with 95% confidence interval and P-value. * and ** Comparison for P value with high-risk attendees.
aDenominator is based on the number of women who have been invited and are eligible for their next three-yearly screen.
Risk feedback of high and moderate breast cancer risk BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.56 1049
Re-attendance at screening. Figures from the 2012–2013 Greater
Manchester NHSBSP showed that among women who attended
their previous mammogram and whose last screen was within the
last 5 years, 39 058 were invited and 32 925 (84.3%) attended.
For women confirmed as high risk (Tyrer-CuzickX8%) at their
risk feedback (n¼ 328–322 originally high risk and 6 originally
moderate risk; Figure 1), the re-attendance rate at the next 3-year
screening was 94.4% (271 out of 287). Re-attendance for those who
were originally high risk (Tyrer-Cuzick X8%) and who did not
attend their risk appointment was significantly lower at 77.4% (89
of 115) (Po0.0001; Table 4).
For women confirmed as low risk (Tyrer-Cuzicko1.5%) at their
risk feedback (n¼ 89), the re-attendance rate at the next 3-year
screening was lower for the 76 called (84.2%) compared with high-
risk attenders (95%; P¼ 0.004).
Overall re-attendance at the next three-yearly screen for women
who attended their risk appointments for all three risk categories
was 92.9% (391 out of 421). Re-attendance was significantly higher
for high-risk women invited for feedback (Po0.0001) than usual
re-attendance rates in Greater Manchester, but was not signifi-
cantly lower for low-risk attenders and non-counselled women.
Risk perception. Three-hundred and twenty-eight of 568 (58%)
high-risk and 58 of 106 (55%) low-risk women completed risk
perception questionnaires. Fifty-three high-risk women had
previously attended the FHC for risk assessment between 1990
and 2010 (median¼ 1996) some 4–24 years (median¼ 15) prior to
their risk assessment in PROCAS. High-risk women ascribed
higher comparative risk categories to themselves than low-risk
women (Table 3; Po0.001) and previously counselled women had
more accurate risk perceptions for themselves and for the general
population than low-risk women’s perceptions. When asked to
estimate the risk for the general population, only a minority (37%
high, 33% low) gave the ‘correct’ current lifetime risk range of 10–
12%. Meanwhile 52% of women who had previously received risk
counselling gave the correct current lifetime risk of breast cancer
for the general population. Receipt of risk information did not
significantly change low-risk women’s intentions to attend
subsequent mammograms, with only one expressing a desire to
cease screening.
DISCUSSION
This is the first study to show it is possible to collect and feedback
risk information to women at both high and low risk of breast
cancer, in the context of a population-based mammographic
screening programme. Women at high risk were more likely, than
those at low-risk, to perceive their risk as elevated prior to
counselling. This is most likely due to the presence of a family
history of breast cancer. Accordingly, both attendance at risk
counselling (74% in high risk vs 55% in low risk, Pp0.0001) and
re-attendance at the subsequent mammography screen (92% vs
84%, respectively, P¼ 0.05) were higher in women counselled at
high risk compared with those with low risk. Indeed, high-risk
women were more likely to re-attend subsequent mammography
than women in the general screening population. Low-risk women
were reluctant to discontinue screening. It is reassuring to
screening programmes, which are judged by the re-attendance
rate, there was not a significant drop in attendance at the
subsequent screen after risk assessment is introduced.
Women at high lifetime risk of breast cancer are now
recommended annual mammography screening between 40 and
60 years in the UK (McIntosh et al, 2004 updated 2006 and 2013).
There was a high uptake of additional screening in high-risk
women in PROCAS, and the 11% not referred by their GP may be
the GP’s decision rather than the woman’s. It is reassuring that not
only does Tyrer-Cuzick reliably identify women at high risk
(the 3% detection rate can be considered to represent a 3-year
period including lead time – thus 1% annually or 10% over 10
years), but that 41% of those detected on additional screening
have extremely good prognosis stage-1 cancers. While these
numbers are small, for cancers detected on interval screens they
represent an extremely high rate (4 of 280 extra screens). Since all
occurred in womeno63 even the grade 1 cancer would likely have
presented in the woman’s lifetime and might not be considered an
‘over-diagnosis’.
This study has also assessed risk perception. Unlike previous
studies that were based mainly on women with concerns about
their breast cancer risk due to family history (Evans et al, 1993,
1994; Hopwood et al, 2001), the present study addresses risk
perceptions of women at either end of the spectrum from the
general population, the majority of whom had not been assessed
previously. Risk perception was, as reported previously not overly
accurate (Evans et al, 1993; McCaul and O’Donnell, 1998;
Hopwood et al, 2001), with 66% of low-risk women rating
themselves at ‘average’ risk. High-risk women were more likely to
assess their risk as above average compared with low-risk women,
in both comparative and absolute terms. Perception of population
risk was not statistically significantly different between the two
previously uncounselled groups. However, those seen previously in
the FHC had more accurate overall risk perception as previously
reported (Evans et al, 1994). This finding supports the efficacy of
counselling in a health-care setting at producing accurate risk
perceptions, in contrast to the mere provision of risk in settings
outside of the health-care system (Dillard et al, 2006; Paci et al,
2013). Being informed of one’s risk did not impact on intentions to
change screening behaviour. This is in opposition to the weight of
cross-sectional studies (McCaul et al, 1996) but in line with
evidence from prospective studies where the more affective
construct of cancer worry is a more consistent predictor of
mammography attendance (Hay et al, 2006; Walker et al, 2014).
There are limitations to the present study. The 38% uptake may
have biased the population to women with higher risks. A survey
alongside our FHC did not suggest this was the case (Evans et al,
2014). The drop-off from B95% wishing to receive risk
information and who then declined is disappointing, and from
women’s comments is largely down to inconvenience. It is likely
uptake would have been much higher if a letter giving feedback had
been offered. Our original report on the first 10 000 women noted
that uptake to PROCAS was lower in areas with higher deprivation
as was uptake to screening (Evans et al, 2012). This trend has
continued and there were no other biases we could detect, with
uptake similar across age groups, except a slightly higher uptake in
women attending their first screening appointment (Evans et al,
2012). The present report adds data on risk perception, follow-up
Table 5. Breast cancers identified on interval screening
Individual Age (years) Cancer
1 54 7mm grade 1 node-negative invasive ductal carcinoma (IDC)
2 63 28mm grade 3 node-positive IDC with ductal carcinoma in situ (DCIS)
3 58 25mm focus and 7mm focus of grade 2 node-negative invasive lobular carcinoma with lobular carcinoma in situ (LCIS)
4 51 Grade 2 IDC 10mm and a separate 4.5mm focus of grade 1 node-negative invasive tubular carcinoma with DCIS
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and re-attendance and accuracy of risk prediction (risk perception
was based on a validated questionnaire that used lifetime risk as
opposed to 10-year risk). Although uptake to PROCAS is relatively
low, it rises to 60% when dedicated study staff are present at the
time of screening, and would likely rise further if it became a
routine part of screening rather than a ‘study’. We have not
conducted a formal assessment of the impact of risk information
on anxiety and intention to change behaviour although this is
planned in a new prospective arm to the study. There were some
inaccuracies in completion of the questionnaires, particularly in
relation to bilateral disease and timing of the menopause. In future,
an online version of the questionnaire with prompts and pop up
questions is likely to improve accuracy. Certainly if only a paper
questionnaire is used, confirming details in those whose manage-
ment may change is important as risk category may change
substantially. We believe an online questionnaire with prompts and
an inbuilt risk algorithm, such as Tyrer-Cuzick, which could also
incorporate automatic measurement of mammographic density, is
likely to be the most feasible way forward to provide accurate risk
provision. This would be an absolute requirement if risk stratified
screening were to be implemented.
In conclusion, the present study has shown it is feasible to
obtain risk information in the context of a national breast
screening programme. It is also feasible to feedback risk
information to women taking part in population-based breast
screening. For practical deployment at-scale, automation of
processes will be necessary, ideally with interactive online data-
capture and error-correction. Further research is necessary to find
the safest and most effective means to feedback risk information,
especially to high-risk women and, in particular, who should be
responsible for their management. For example, what accompany-
ing information about risk reduction strategies is required? Is an
accompanying leaflet sufficient? Overall it is encouraging that
reattendance rates are extremely high in those fed-back high-risks.
It seems likely that interval cancer rates could be reduced and
overall outcome after diagnosis improved, but this requires further
investigation. Further breast cancer risk could be reduced by the
offer of preventive therapy in women detected to be at moderate/
high risk (McIntosh et al, 2004 updated 2006 and 2013).
Research in context
1. Risk assessment and provision of risk information is feasible in a
population breast screening programme
2. The majority of women wish to know their breast cancer risk
3. Identification of high-risk women with provision of risk information
enhances screening attendance
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